Compare MOGO & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MOGO | AKTX |
|---|---|---|
| Founded | 2003 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.6M | 14.4M |
| IPO Year | N/A | N/A |
| Metric | MOGO | AKTX |
|---|---|---|
| Price | $1.10 | $0.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $4.00 | $3.30 |
| AVG Volume (30 Days) | 116.8K | ★ 1.4M |
| Earning Date | 11-07-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $29,215,516.00 | N/A |
| Revenue This Year | $63.05 | N/A |
| Revenue Next Year | $5.58 | N/A |
| P/E Ratio | $5.16 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.74 | $0.26 |
| 52 Week High | $3.83 | $1.73 |
| Indicator | MOGO | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.65 | 39.04 |
| Support Level | $1.14 | $0.26 |
| Resistance Level | $1.22 | $0.47 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 0.00 | 38.34 |
Mogo Inc is a Canadian-based financial technology company. It offers a finance application to consumers with solutions that help them to control their financial health. At Mogo, users can sign up for a free account and get access to products and solutions that help users to monitor their credit score, protect themselves from identity fraud, control their spending, and borrow responsibly. Company offers digital loans and mortgages and also offer a digital payments platform that powers next-generation card programs for both established world-wide corporations and fintech companies in Europe and Canada.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.